138 related articles for article (PubMed ID: 21518780)
1. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.
Wahlin BE; Sundström C; Holte H; Hagberg H; Erlanson M; Nilsson-Ehle H; Lindén O; Nordström M; Ostenstad B; Geisler CH; Brown Pde N; Lehtinen T; Maisenhölder M; Tierens AM; Sander B; Christensson B; Kimby E
Clin Cancer Res; 2011 Jun; 17(12):4136-44. PubMed ID: 21518780
[TBL] [Abstract][Full Text] [Related]
2. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
Wahlin BE; Sander B; Christensson B; Kimby E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
[TBL] [Abstract][Full Text] [Related]
3. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
4. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
5. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
[TBL] [Abstract][Full Text] [Related]
6. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
[TBL] [Abstract][Full Text] [Related]
7. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
8. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
[TBL] [Abstract][Full Text] [Related]
9. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
[TBL] [Abstract][Full Text] [Related]
11. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Anraku M; Cunningham KS; Yun Z; Tsao MS; Zhang L; Keshavjee S; Johnston MR; de Perrot M
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):823-9. PubMed ID: 18374762
[TBL] [Abstract][Full Text] [Related]
12. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
13. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
14. Case of paraneoplastic pemphigus with follicular lymphoma treated with rituximab.
Aoi J; Makino K; Sakai K; Masuguchi S; Fukushima S; Jinnin M; Inoue Y; Koga H; Hashimoto T; Ihn H
J Dermatol; 2013 Apr; 40(4):285-6. PubMed ID: 23398274
[No Abstract] [Full Text] [Related]
15. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
17. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
[TBL] [Abstract][Full Text] [Related]
19. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
20. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Weng WK; Levy R
J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
